BKM Wealth Management LLC Has $599,000 Position in Sanofi (NASDAQ:SNY)

BKM Wealth Management LLC boosted its position in shares of Sanofi (NASDAQ:SNY) by 140.8% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 10,386 shares of the company’s stock after buying an additional 6,072 shares during the quarter. BKM Wealth Management LLC’s holdings in Sanofi were worth $599,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of SNY. Northwest Investment Counselors LLC bought a new position in Sanofi in the third quarter valued at about $29,000. POM Investment Strategies LLC acquired a new position in shares of Sanofi during the 2nd quarter worth about $25,000. Larson Financial Group LLC grew its holdings in shares of Sanofi by 480.8% in the 1st quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock valued at $29,000 after acquiring an additional 500 shares in the last quarter. Register Financial Advisors LLC bought a new stake in Sanofi during the first quarter worth about $29,000. Finally, Palisade Asset Management LLC bought a new position in Sanofi in the first quarter valued at approximately $31,000. 10.04% of the stock is currently owned by institutional investors.

Sanofi Trading Up 4.4 %

NASDAQ:SNY opened at $54.34 on Friday. The firm’s fifty day moving average is $56.08 and its 200-day moving average is $51.72. Sanofi has a 52 week low of $42.63 and a 52 week high of $58.97. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The firm has a market cap of $137.63 billion, a P/E ratio of 27.31, a P/E/G ratio of 1.40 and a beta of 0.60.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Thursday, July 25th. The company reported $0.93 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.05. The firm had revenue of $10.75 billion for the quarter, compared to analysts’ expectations of $16.86 billion. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The company’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.95 EPS. Equities analysts expect that Sanofi will post 4.23 earnings per share for the current year.

Wall Street Analyst Weigh In

SNY has been the topic of several research analyst reports. Citigroup raised shares of Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Monday, October 14th. Finally, Argus increased their target price on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Three analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.